

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Attorney Docket No. <b>056291-5215</b>		Application No. <b>10/554,202</b>	
<b>RESUBMISSION OF</b> <b>PTO Form 1449</b> <b>December 4, 2008</b>				Applicants: <b>Robert Hugh BRADBURY et al.</b>			
				Filing Date: <b>October 24, 2005</b>		Group Art Unit: <b>1624</b>	

  

U.S. PATENT DOCUMENTS							
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date	
/T.N./	1.	US 2003/0186995	October 2, 2003	Kath et al.			
/T.N./	2.	US 2004/0048880	March 11, 2004	Himmelsbach et al.			

  

FOREIGN PATENT DOCUMENTS						
Initial	Document No.	Date	Country	Inventor/Assignee	Translation	
/T.N./	3.	CA 2476008	October 9, 2003	Canada	Boehringer Ingelheim Pharma	
/T.N./	4.	CA 2543649	May 12, 2005	Canada	Boehringer Ingelheim International GmbH	
/T.N./	5.	WO 01/21596	March 29, 2001	WIPO	AstraZeneca AB	
/T.N./	6.	WO 2004/046101	June 3, 2004	WIPO	Array Biopharma Inc.	
/T.N./	7.	WO 2005/041973	May 12, 2005	WIPO	Boehringer Ingelheim International GmbH	
/T.N./	8.	WO 2005/097134	October 20, 2005	WIPO	The Scripps Research Institute	

  

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
/T.N./	9.	Ballard et al. "Developing a small molecule erbB2 inhibitor: challenges with optimising DMPK properties" Poster - Presented at DMDG Cambridge (February 6, 2008).					
/T.N./	10.	Ballard et al. "Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorg Med Chem Lett. 17(22):6326-6329 (2007).					
/T.N./	11.	Barlaam et al. "A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorganic & Medicinal Chemistry Letters 18(2):674-678 (2008).					
/T.N./	12.	Barlaam et al. "Indazolylamino/Anilinoquinazolines Bearing a C-5 substitution as erbB2 kinase inhibitors: Structure-activity relationships and identification of a candidate drug" at AACR in 2007					
/T.N./	13.	Barlaam et al. "Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorganic & Medicinal Chemistry Letters 18(6):1799-1803 (2008).					
/T.N./	14.	Barlaam et al. "Indazolylamino/Anilinoquinazolines Bearing a C-5 Substitution As erbB2 Kinase Inhibitors: Structure-Activity Relationships and Identification of a Candidate Drug" Poster number P044, presented at XXth International Symposium on Medicinal Chemistry (EFMC-ISM-C 2008), Vienna, Austria, August 31 - September 4, 2008.					
/T.N./	15.	Cockerill et al. "Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFR and c-erbB-2" Bioorganic & Medicinal Chemistry Letters 11(11):1401-1405 (2001).					
/T.N./	16.	Ducray et al. "Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors" Bioorganic & Medicinal Chemistry Letters 18(3):959-962 (2008).					
/T.N./	17.	Gaul et al. "Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines" Bioorganic & Medicinal Chemistry Letters 13(4):637-640 (2003).					
/T.N./	18.	Harris et al. "Systematic variation of a key quinazoline core" Presented at the XXII European Colloquium on Heterocyclic Chemistry (XXII ECHC-2006) Bari, Italy, September 2-6, 2006.					
/T.N./	19.	Hennequin et al. "N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor" J Med Chem. 49(22):6465-6488 (2006).					
/T.N./	20.	Jani et al. "Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor" Cancer Research 67(20):9887-9893 (2007).					

  

Examiner	Date Considered	
/Tamthom Truong/		08/12/2009

**Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Use several sheets if necessary)

Application No.  
10/554,202

## RESUBMISSION OF

PTO Form 1449  
December 4, 2008

**Filing Date: October 24, 2005**

Group Art Unit: 1624

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
---------	--------------	------	------	-------	-----------	-------------

Category	Sub-category	Value	Unit	Period	Notes

		Document No.	Date	Country	Class	Sub-Class	Translation
--	--	--------------	------	---------	-------	-----------	-------------

		2019-2020	2020-21	2021-22	2022-23	2023-24	2024-25

/T.N./	21. Klutchko et al. "Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors" J Med Chem. 49(4):1475-1485 (2006)
--------	--

T.N./	22. Petrov et al. "Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series" Bioorg Med Chem Lett. 16(17):4686-4691 (2006) .
-------	---

Examiner

/Tamthom Truong/

Date Considered

08/12/2009

**Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)  <b><u>RESUBMISSION OF</u></b> <b>PTO Form 1449</b> <b>June 8, 2007</b>	Attorney Docket No. <b>056291-5215</b>	Application No. <b>10/554,202</b>
	Applicants: <b>BRADBURY et al.</b>	
	Filing Date: <b>October 24, 2005</b>	Group Art Unit: <b>1624</b>

**U.S. PATENT DOCUMENTS**

Initial	No.	Document No.	Date	Name	Class	Sub-Class	Filing Date
/T.N./	1.	US 4,335,127	June 15, 1982	Vandenberk et al.			
/T.N./	2.	US 4,921,863	May 1, 1990	Sugimoto et al.			
/T.N./	3.	US 6,297,258	October 2, 2001	Wissner et al.			
/T.N./	4.	US 6,562,319	May 13, 2003	Mishani et al.			
/T.N./	5.	US 6,972,288	December 6, 2005	Himmelsbach et al.			
/T.N./	6.	US 20020082270	June 27, 2002	Himmelsbach et al.			
/T.N./	7.	US 20020128553	September 12, 2002	Mishani et al.			
/T.N./	8.	US 20040176361	September 9, 2004	Fujio et al.			

**FOREIGN PATENT DOCUMENTS**

Initial	No.	Document No.	Date	Country	Inventor/Assignee	Translation
/T.N./	9.	EP 0288563	November 2, 1988	EPO	Eisai Co., Ltd.	
/T.N./	10.	EP 1230919	August 14, 2002	EPO	Warner-Lambert Company	
/T.N./	11.	EP 1369418	December 10, 2003	EPO	Mitsubishi Pharma Corporation	
/T.N./	12.	WO 88/02365	April 7, 1988	WIPO	Eisai Co., Ltd.	US 4,921,863
/T.N./	13.	WO 99/06378	February 11, 1999	WIPO	Warner-Lambert Company	
/T.N./	14.	WO 00/09481	February 24, 2000	WIPO	Takeda Chemical Industries, Ltd.	Claims
/T.N./	15.	WO 00/18740	April 6, 2000	WIPO	American Cyanamid Company	
/T.N./	16.	WO 00/24718	May 4, 2000	WIPO	Akzo Nobel N.V.	
/T.N./	17.	WO 01/07432	February 1, 2001	WIPO	Smithkline Beecham P.L.C.	
/T.N./	18.	WO 01/21597	March 29, 2001	WIPO	AstraZeneca AB	
/T.N./	19.	WO 02/056882	July 25, 2002	WIPO	Smithkline Beecham P.L.C.	
/T.N./	20.	WO 02/062767	August 15, 2002	WIPO	Japan Energy Corporation	Yes
/T.N./	21.	WO 02/066445	August 29, 2002	WIPO	Mitsubishi Pharma Corporation	EP 1369418
/T.N./	22.	WO 02/068409	September 6, 2002	WIPO	Merck & Co., Inc.	
/T.N./	23.	WO 02/073235	September 19, 2002	WIPO	Yissum Research Development Company of The Hebrew University Of Jerusalem	
/T.N./	24.	WO 02/076976	October 3, 2002	WIPO	Bayer Corporation	
/T.N./	25.	WO 02/092577	November 21, 2002	WIPO	AstraZeneca AB	
/T.N./	26.	WO 02/092578	November 21, 2002	WIPO	AstraZeneca AB	
/T.N./	27.	WO 02/094790	November 28, 2002	WIPO	Mitsubishi Pharma Corporation	US 2004176361
/T.N./	28.	WO 02/24684	March 28, 2002	WIPO	Smithkline Beecham P.L.C.	
/T.N./	29.	WO 02/30924	April 18, 2002	WIPO	AstraZeneca AB	
/T.N./	30.	WO 02/34744	May 2, 2002	WIPO	AstraZeneca AB	
/T.N./	31.	WO 02/44166	June 6, 2002	WIPO	AstraZeneca AB	
/T.N./	32.	WO 02/48117	June 20, 2002	WIPO	Fujisawa Pharmaceutical Co., Ltd.	
/T.N./	33.	WO 03/049740	June 19, 2003	WIPO	Pfizer Products Inc.	
/T.N./	34.	WO 04/064718	August 5, 2004	WIPO	T.K. Signal Ltd.	
/T.N./	35.	WO 06/092573	September 8, 2006	WIPO	AstraZeneca AB	
/T.N./	36.	WO 06/092574	September 8, 2006	WIPO	AstraZeneca AB	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

Examiner /Tamthom Truong/	Date Considered 08/12/2009
<b>Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Attorney Docket No. <b>056291-5215</b>		Application No. <b>10/554,202</b>	
<b>RESUBMISSION OF</b> <b>PTO Form 1449</b> <b>February 27, 2007</b>				Applicants: <b>BRADBURY et al.</b>			
				Filing Date: <b>October 24, 2005</b>		Group Art Unit: <b>1624</b>	

  

U.S. PATENT DOCUMENTS							
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date	
/T.N./	1.	US 4,322,420	March 30, 1982	514	266.4	September 11, 1979	
/T.N./	2.	US 4,640,920	February 3, 1987	514	248	June 13, 1985	
/T.N./	3.	US 5,405,843	April 11, 1995	514	183	September 9, 1993	
/T.N./	4.	US 5,721,237	February 24, 1998	514	266.1	June 6, 1995	
/T.N./	5.	US 5,747,498	May 5, 1998	514	266.4	May 28, 1996	
/T.N./	6.	US 5,929,080	July 27, 1999	514	266.4	April 21, 1998	
/T.N./	7.	US 5,962,458	October 5, 1999	514	266.21	December 17, 1996	
/T.N./	8.	US 6,004,967	December 21, 1999	514	266.4	September 11, 1997	
/T.N./	9.	US 6,046,206	April 4, 2000	514	266.21	April 30, 1997	
/T.N./	10.	US 6,117,433	September 12, 2000	424	400	April 28, 1998	
/T.N./	11.	US 6,313,130	November 6, 2001	514	266.24	July 28, 2000	
/T.N./	12.	US 6,326,373	December 4, 2001	514	266.1	October 16, 2000	
/T.N./	13.	US 6,384,223	May 7, 2002	544	293	May 4, 2000	

  

FOREIGN PATENT DOCUMENTS					
Document No.	Date	Country	Inventor/Assignee	Translation	
/T.N./ 14.	EP 0 326 330	July 24, 2002	EPA	Dow AgroSciences LLC	
/T.N./ 15.	EP 0 520 722	December 27, 1996	EPA	Zeneca Limited	
/T.N./ 16.	EP 0 566 226	November 8, 1995	EPA	Zeneca Limited	
/T.N./ 17.	EP 0 602 851	October 9, 1996	EPA	Zeneca Limited	
/T.N./ 18.	EP 0 787 722	August 6, 1997	EPA	American Cyanamid Company	
/T.N./ 19.	EP 0 837 063	April 22, 1998	EPA	Pfizer Inc.	
/T.N./ 20.	GB 2,295,387	May 29, 1996	United Kingdom	Glaxo Inc	
/T.N./ 21.	JP-08-003144	January 17, 1996	Japan	Chugai Pharmaceut Co Ltd	
/T.N./ 22.	JP-11-189586	July 13, 1999	Japan	Kirin Brewery Co Ltd	
/T.N./ 23.	WO 92/20642	November 26, 1992	WIPO	Rhône-Poulenc Rorer Inter. Inc.	
/T.N./ 24.	WO 93/08170	April 29, 1993	WIPO	American Home Products Corp.	
/T.N./ 25.	WO 93/17682	September 16, 1993	WIPO	Abbott Laboratories	
/T.N./ 26.	WO 95/15758	June 15, 1995	WIPO	Rhône-Poulenc Rorer Pharma, Inc.	
/T.N./ 27.	WO 96/09294	March 28, 1996	WIPO	The Wellcome Foundation Limited	
/T.N./ 28.	WO 96/15118	May 23, 1996	WIPO	Zeneca Limited	
/T.N./ 29.	WO 96/16960	June 6, 1996	WIPO	Zeneca Limited	
/T.N./ 30.	WO 96/30347	October 3, 1996	WIPO	Pfizer Inc.	
/T.N./ 31.	WO 96/33977	October 31, 1996	WIPO	Zeneca Limited	
/T.N./ 32.	WO 96/33978	October 31, 1996	WIPO	Zeneca Limited	
/T.N./ 33.	WO 96/33979	October 31, 1996	WIPO	Zeneca Limited	
/T.N./ 34.	WO 96/33980	October 31, 1996	WIPO	Zeneca Limited	

  

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
Examiner	Date Considered	
/Tamthorn Truong/	08/12/2009	

**Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Attorney Docket No. <b>056291-5215</b>		Application No. <b>10/554,202</b>	
<b>RESUBMISSION OF</b> <b>PTO Form 1449</b> <b>February 27, 2007</b>				Applicants: <b>BRADBURY <i>et al.</i></b>			
				Filing Date: <b>October 24, 2005</b>		Group Art Unit: <b>1624</b>	
<b>U.S. PATENT DOCUMENTS</b>							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document No.	Date	Country	Inventor/Assignee		Translation
<del>/T.N./</del>	35.	WO 96/33981	October 31, 1996	WIPO	Zeneca Limited		
<del>/T.N./</del>	36.	WO 96/39145	December 12, 1996	WIPO	Rhone-Poulenc Rorer Pharmaceuticals Inc.		
<del>/T.N./</del>	37.	WO 97/03069	January 30, 1997	WIPO	Glaxo Group Limited		
<del>/T.N./</del>	38.	WO 97/11692	April 3, 1997	WIPO	Osteoarthritis Sciences, Inc.		
<del>/T.N./</del>	39.	WO 97/13771	April 17, 1997	WIPO	Glaxo Group Limited		
<del>/T.N./</del>	40.	WO 97/22596	June 26, 1997	WIPO	Zeneca-Pharma S.A.		
<del>/T.N./</del>	41.	WO 97/30034	August 21, 1997	WIPO	Zeneca Limited		
<del>/T.N./</del>	42.	WO 97/30035	August 21, 1997	WIPO	Zeneca Pharma S.A.		
<del>/T.N./</del>	43.	WO 97/30034	August 21, 1997	WIPO	Zeneca Limited		
<del>/T.N./</del>	44.	WO 97/38983	October 23, 1997	WIPO	Warner-Lambert Company		
<del>/T.N./</del>	45.	WO 97/38994	October 23, 1997	WIPO	Zeneca Limited		
<del>/T.N./</del>	46.	WO 98/02434	January 22, 1998	WIPO	Glaxo Group Limited		
<del>/T.N./</del>	47.	WO 98/02437	January 22, 1998	WIPO	Glaxo Group Limited		
<del>/T.N./</del>	48.	WO 98/02438	January 22, 1998	WIPO	Glaxo Group Limited		
<del>/T.N./</del>	49.	WO 98/13354	April 2, 1998	WIPO	Zeneca Pharma S.A.		
<del>/T.N./</del>	50.	WO 98/38984	September 11, 1998	WIPO	Sugen, Inc.		
<del>/T.N./</del>	51.	WO 98/50038	November 12, 1998	WIPO	American Cyanamid Company		
<del>/T.N./</del>	52.	WO 98/50370	November 12, 1998	WIPO	Sugen, Inc.		
<del>/T.N./</del>	53.	WO 99/09016	February 25, 1999	WIPO	American Cyanamid Company		
<del>/T.N./</del>	54.	WO 99/24037	May 20, 1999	WIPO	American Cyanamid Company		
<del>/T.N./</del>	55.	WO 99/35132	July 15, 1999	WIPO	Glaxo Group Limited		
<del>/T.N./</del>	56.	WO 99/35146	July 15, 1999	WIPO	Glaxo Group Limited		
<del>/T.N./</del>	57.	WO 99/61428	December 2, 1999	WIPO	Parker Hughes Institute		
<del>/T.N./</del>	58.	WO 00/00202	January 6, 2000	WIPO	Uckun, Fatih, M.		
<del>/T.N./</del>	59.	WO 00/06555	February 10, 2000	WIPO	American Home Products Corporation		
<del>/T.N./</del>	60.	WO 00/10981	March 2, 2000	WIPO	Parker Hughes Institute		
<del>/T.N./</del>	61.	WO 00/20402	April 13, 2000	WIPO	Zeneca Limited		
<del>/T.N./</del>	62.	WO 00/44728	August 3, 2000	WIPO	Pfizer Products Inc.		
<del>/T.N./</del>	63.	WO 00/47212	August 17, 2000	WIPO	Zeneca-Pharma S.A.		
<del>/T.N./</del>	64.	WO 00/51587	September 8, 2000	WIPO	Parker Hughes Institute		
<del>/T.N./</del>	65.	WO 00/51991	September 8, 2000	WIPO	Boehringer Ingelheim Pharma KG		
<del>/T.N./</del>	66.	WO 00/55141	September 21, 2000	WIPO	Boehringer Ingelheim Pharma KG		
<del>/T.N./</del>	67.	WO 00/73260	December 7, 2000	WIPO	Celltech Chiroscience Limited		
<del>/T.N./</del>	68.	WO 01/12227	February 22, 2001	WIPO	American Cyanamid Company		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
Examiner	/Tamthom Truong/			Date Considered	08/12/2009		
<b>Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Attorney Docket No. <b>056291-5215</b>		Application No. <b>10/554,202</b>	
<b>RESUBMISSION OF</b> <b>PTO Form 1449</b> <b>February 27, 2007</b>							
<b>U.S. PATENT DOCUMENTS</b>							
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date	
<b>FOREIGN PATENT DOCUMENTS</b>							
/T.N./	69.	WO 01/21594	March 29, 2001	WIPO	AstraZeneca AB		Translation
/T.N./	70.	WO 01/21595	March 29, 2001	WIPO	AstraZeneca AB		
/T.N./	71.	WO 01/32632	May 10, 2001	WIPO	Eli Lilly And Company		
/T.N./	72.	WO 01/45641	June 28, 2001	WIPO	Parker Hughes Institute		
/T.N./	73.	WO 01/77085	October 18, 2001	WIPO	AstraZeneca AB		
/T.N./	74.	WO 01/94341	December 13, 2001	WIPO	AstraZeneca AB		
/T.N./	75.	WO 01/98277	December 27, 2001	WIPO	Pfizer Products Inc.		
/T.N./	76.	WO 02/18372	March 7, 2002	WIPO	Boehringer Ingelheim Pharma KG		Abstract
/T.N./	77.	WO 02/41882	May 30, 2002	WIPO	NOVARTIS AG		
/T.N./	78.	WO 03/040108	May 15, 2003	WIPO	AstraZeneca AB		
/T.N./	79.	WO 03/040102	May 15, 2003	WIPO	AstraZeneca AB		
/T.N./	80.	WO 03/082290	October 9, 2003	WIPO	Boehringer Ingelheim Pharma GmbH & Co.		
/T.N./	81.	WO 03/082831	October 9, 2003	WIPO	AstraZeneca AB		
/T.N./	82.	WO 2004/006846	January 22, 2004	WIPO	Exelixis, Inc.		
/T.N./	83.	WO 2004/096226	November 11, 2004	WIPO	AstraZeneca AB		
/T.N./	84.	WO 2005/012290	November 4, 2004	WIPO	AstraZeneca AB		
/T.N./	85.	WO 2005/013998	February 17, 2005	WIPO	AstraZeneca AB		
/T.N./	86.	WO 2005/026150	March 24, 2005	WIPO	AstraZeneca AB		
/T.N./	87.	WO 2005/026150	March 24, 2005	WIPO	AstraZeneca AB		
/T.N./	88.	WO 2005/026152	March 24, 2005	WIPO	AstraZeneca AB		
/T.N./	89.	WO 2005/026156	March 24, 2005	WIPO	AstraZeneca AB		
/T.N./	90.	WO 2005/026157	March 24, 2005	WIPO	AstraZeneca AB		
/T.N./	91.	WO 2005/028469	March 31, 2005	WIPO	AstraZeneca AB		
/T.N./	92.	WO 2005/028470	March 31, 2005	WIPO	AstraZeneca AB		
/T.N./	93.	WO 2005/030757	April 7, 2005	WIPO	AstraZeneca AB		
/T.N./	94.	WO 2005/030765	April 7, 2005	WIPO	AstraZeneca AB		
/T.N./	95.	WO 2005/051923	June 9, 2005	WIPO	AstraZeneca AB		
/T.N./	96.	WO 2005/075439	August 18, 2005	WIPO	AstraZeneca AB		
/T.N./	97.	WO 2005/118572	December 15, 2005	WIPO	AstraZeneca AB		
/T.N./	98.	WO 2006/008526	January 26, 2006	WIPO	AstraZeneca AB		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
/T.N./	99.	Ballard et al. "5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorg Med Chem Lett. 15(19):4226-4229 (2005).					
/T.N./	100.	Ballard et al. "Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket" Bioorg Med Chem Lett. 16(6):1633-1637 (2006).					
Examiner			/Tamthom Truong/		Date Considered		
					08/12/2009		
<b>Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)		Attorney Docket No. <b>056291-5215</b>		Application No. <b>10/554,202</b>		
		Applicants: <b>BRADBURY et al.</b>				
<b>RESUBMISSION OF</b> <b>POT Form 1449</b> <b>February 27, 2007</b>		Filing Date: <b>October 24, 2005</b>		Group Art Unit: <b>1624</b>		
<b>U.S. PATENT DOCUMENTS</b>						
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
<b>FOREIGN PATENT DOCUMENTS</b>						
	Document No.	Date	Country	Class	Sub-Class	Translation
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)</b>						
/T.N./	101.	Ballard et al. "Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics" Bioorg Med Chem Lett. 16(18):4908-4912 (2006) .				
/T.N./	102.	Barker et al. "Studies leading to the identification of ZD1839 (Iressa <sup>TM</sup> ): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer" <i>Bioorganic and Medicinal Chemistry Letters</i> 11(14):1911-1914 (2001) .				
/T.N./	104.	Bridges et al. "Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor" J. Med. Chem. 39(1):267-276 (1996) .				
/T.N./	104.	Denny et al. "Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site for the epidermal growth factor receptor in vitro" Clinical and Experimental Pharmacology and Physiology 23:424-427 (1996).				
/T.N./	105.	Harris et al. "Facile synthesis of 7-amino anilinoquinazolines via direct amination of the quinazoline core" Tetrahedron letters 46(43): 7381-7384 (2005) .				
/T.N./	106.	Harris et al. "Selective alkylation of a 6,7-dihydroxyquinazoline" Tetrahedron letters 46(45):7715-7719 (2005) .				
/T.N./	104.	Hennequin et al. "Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGFR receptor tyrosine kinase inhibitors" Bioorg Med Chem Lett. 16(10):2672-2676 (2006) .				
/T.N./	108.	Hennequin et al. "Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors" J. Med. Chem. 45 (6):1300 -1312 (2002) .				
/T.N./	104.	Rewcastle et al. "Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor" J. Med. Chem. 35:3452-3457 (1995) .				
/T.N./	110.	Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor" J. Biol. Chem. 277(48):46265-46272 (2002) .				
/T.N./	111.	Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997) .				
/T.N./	112.	Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998) .				
/T.N./	113.	Tsou et al. "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001) .				
/T.N./	114.	Vema et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003) .				
Examiner		/Tamthorn Truong/		Date Considered		08/12/2009

**Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

**RESUBMISSION OF****PTO Form 1449****October 24, 2005**

ATTY DOCKET NO.

**056291-5215-US**

APPLICATION NO

**To be assigned**

APPLICANT

**Robert Hugh BRADBURY et al.**

FILING DATE

**October 24, 2005**

GROUP

**XXXXXXXXXX****1624****FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	INVENTOR/ASSIGNEE	TRANSLATION	
						YES	NO
/T.N./	B01	WO 96/15118	05/1996	PCT	Zeneca Limited		
/T.N./	B02	WO 03/040108	05/2003	PCT	AstraZeneca AB		
	B03						
	B04						
	B05						

EXAMINER

**/Tamthom Truong/**

DATE CONSIDERED

**08/12/2009**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.